The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Draxis Specialty Pharmaceuticals

I-131! Getchyer Rrrred Hot I-131 Here! Health Canada Approves Alternate Source for Thryoid Cancer Treatment

683px-Schematicky_atomDraximage has been approved by Health Canada to supply I-131 from South Africa’s Safari reactor to treat Canadian thyroid cancer patients. As the Health Canada press release points out, “[p]roduction of I-131 in Canada was interrupted by the unplanned shutdown of the Chalk River National Research Universal reactor (NRU) in May 2009.” Draximage is a division of DRAXIS Specialty Pharmaceuticals, which was bought by Jubliant Organosys in May 2008.

Update: Good thing too, because the Chalk River reactor may be out of commission through the Fall or even into 2010.

Bookmark and Share


Get every new post delivered to your Inbox.

Join 128 other followers